Relmacabtagene Autoleucel (Carteyva)
CD19-directed CAR-T cell therapy approved in China for relapsed or refractory B-cell lymphoma.
What is Relmacabtagene Autoleucel?
What it targets
Targets CD19, a protein expressed on the surface of B-cell lymphoma cells
Who it may help
Adults with relapsed or refractory B-cell lymphoma after prior systemic therapy
Why testing matters
CD19 testing, PET-CT staging, organ function tests, and CAR-T centre eligibility assessment
Which cancers can Relmacabtagene Autoleucel treat?
Carteyva is NMPA-approved in China for the following B-cell lymphoma types under specific treatment-line criteria.
| Large B-cell lymphoma | For selected adults with relapsed or refractory disease after two or more prior lines of systemic therapy in China |
| Diffuse large B-cell lymphoma (DLBCL) | Included under the large B-cell lymphoma approval; eligibility depends on pathology subtype and prior treatment history |
| Follicular lymphoma (FL) | For selected adults whose disease is refractory or has relapsed within the approved timing after second-line or later therapy |
| Mantle cell lymphoma (MCL) | NMPA-approved for selected adults with relapsed or refractory MCL after two or more lines including BTK inhibitor therapy |
| Other CD19-positive lymphomas | Not standard use unless supported by approval, specialist decision, or clinical trial enrolment |
Who may benefit from Relmacabtagene Autoleucel?
Eligibility depends on lymphoma subtype, CD19 status, prior treatment, organ function, and CAR-T centre assessment.
- Confirmed B-cell lymphoma with documented CD19-positive disease
- Relapsed or refractory large B-cell lymphoma after two or more prior systemic therapy lines
- Follicular lymphoma meeting NMPA-approved relapsed or refractory treatment criteria
- Mantle cell lymphoma relapsed after two or more lines including a BTK inhibitor
- Adequate heart, lung, liver, and kidney function for CAR-T treatment
- No uncontrolled active infection at the time of evaluation
- Disease that can be safely managed during the CAR-T manufacturing period
- Ability to stay at or near a qualified China CAR-T centre for several weeks after infusion
- Treating specialist confirms the expected benefit outweighs the individual risks
How does Relmacabtagene Autoleucel work?
- T-cell collection by leukapheresis
- Cell engineering — adding the CAR
- Cell expansion and quality testing
- Bridging therapy if needed
- Lymphodepleting chemotherapy
- Single CAR-T cell infusion
- Immune activation and lymphoma attack
- Close post-infusion monitoring
Tests needed before Carteyva treatment
A thorough workup is required before CAR-T manufacturing begins to confirm eligibility and establish safety baselines.
| Lymphoma biopsy and pathology | Confirms lymphoma subtype and eligibility for the approved Carteyva indication |
| CD19 testing | By immunohistochemistry or flow cytometry to confirm CD19-positive disease |
| PET-CT or CT staging | Assesses the extent and sites of active lymphoma disease |
| CBC and differential | Baseline blood counts; monitored throughout the CAR-T process |
| Liver and kidney function tests | Required to confirm organ fitness for lymphodepleting chemotherapy and CAR-T infusion |
| Coagulation panel | Baseline coagulation status before lymphodepleting chemotherapy |
| Viral screening | Hepatitis B, hepatitis C, HIV, CMV, and other infections per centre protocol |
| Cardiac assessment | ECG and echocardiogram to confirm heart function before treatment |
| Neurological baseline assessment | To detect pre-existing neurological issues that may affect ICANS risk and monitoring |
| Bone marrow biopsy | Performed when clinically indicated based on lymphoma subtype and disease pattern |
| Review of prior therapy history | All prior chemotherapy, immunotherapy, targeted therapy, BTK inhibitors, and transplant must be documented |
How is Relmacabtagene Autoleucel given?
Carteyva is a one-time intravenous CAR-T cell infusion given at a qualified centre after a multi-step preparation process.
| Infusion type | Single intravenous infusion of autologous engineered CAR-T cells — not a repeating chemotherapy cycle |
| Lymphodepleting chemotherapy | Fludarabine and cyclophosphamide given for 3 days before infusion to prepare the immune environment |
| Infusion setting | Must be administered at a certified CAR-T treatment centre in China with trained medical staff |
| Bridging therapy | Some patients receive short-course bridging treatment during manufacturing to stabilise disease |
| Post-infusion monitoring period | Patients remain near the CAR-T centre for at least 4 weeks; ICU access must be available on-site |
| Duration of CAR-T therapy | Single infusion; however, follow-up monitoring, imaging, and blood tests continue for many months after |
| No home administration | Carteyva cannot be given at home or at a standard oncology clinic — a qualified CAR-T centre is required |
Clinical evidence and potential benefits
Carteyva has shown meaningful responses in patients with relapsed or refractory B-cell lymphomas, including those who had failed multiple prior therapies.
| Overall response in large B-cell lymphoma | Clinical studies have shown substantial overall and complete response rates in patients with relapsed or refractory DLBCL and large B-cell lymphoma |
| Durable remission in some responders | A meaningful proportion of patients who achieve complete response maintain long-term remission, representing potential long-term disease control from a single treatment |
| Benefit in follicular lymphoma | High response rates have been reported in relapsed or refractory follicular lymphoma, with deep and durable remissions observed in a significant subset of patients |
| Response after multiple failed therapies | Carteyva has shown responses even in patients who have progressed after multiple lines of chemotherapy, rituximab-based therapy, and targeted agents |
| One-time personalised treatment | Unlike continuous chemotherapy, Carteyva is a single infusion derived from the patient's own cells, potentially offering lasting disease control without the cumulative toxicity of repeated drug cycles |
| China-based access for international patients | As one of the few NMPA-approved Category 1 CAR-T products in China, Carteyva provides a viable access pathway for eligible international patients unable to access CAR-T in their home country |
Individual responses vary. Not all patients achieve remission. These reflect published clinical and approval data from JW Therapeutics and associated studies.
Side effects of Relmacabtagene Autoleucel
CAR-T therapy produces a distinct side effect profile from standard chemotherapy. Most effects relate to immune activation and are most common in the weeks after infusion.
| Cytokine release syndrome (CRS) | Most common serious side effect; ranges from fever and low blood pressure to severe breathing difficulty; managed with tocilizumab or steroids |
| Immune effector cell-associated neurotoxicity (ICANS) | Can cause confusion, difficulty speaking, tremor, seizures, or altered consciousness; requires close neurological monitoring |
| Fever | Very common in the first 1 to 2 weeks post-infusion; a key early signal of CRS |
| Low blood pressure | Associated with cytokine release; may require IV fluids and vasopressors in severe cases |
| Low white blood cells (neutropenia) | Common after lymphodepleting chemotherapy and CAR-T expansion; increases infection risk for weeks to months |
| Anaemia and low platelets | Common after lymphodepleting chemotherapy; may require transfusions during recovery |
| Infections | Risk is elevated due to low blood counts and long-term B-cell aplasia; antibacterial, antiviral, and antifungal prophylaxis is typically given |
| Fatigue and weakness | Common during and after treatment; usually improves over weeks to months |
| Nausea, diarrhoea, poor appetite | Common during lymphodepleting chemotherapy and early post-infusion period |
| Low immunoglobulin levels (hypogammaglobulinaemia) | Results from B-cell aplasia; some patients need immunoglobulin replacement for months after treatment |
| Headache and tremor | Common neurological symptoms; may be early signs of ICANS requiring medical review |
Contact your doctor or go to hospital immediately if you develop:
- Fever after CAR-T infusion — any temperature of 38°C or above
- Difficulty breathing, low oxygen, or chest tightness
- Confusion, difficulty speaking, or unusual drowsiness
- Tremor, seizure, or inability to write or understand words
- Severe dizziness, fainting, or very low blood pressure
- Signs of infection — chills, pain, redness, or wound changes
- Unusual bleeding or severe bruising
Safety precautions and important warnings
Tell the CAR-T team about all current and recent medications, supplements, and medical history before treatment begins.
- Inform the team of any active or recent infection — treatment may need to be delayed
- Disclose history of hepatitis B, hepatitis C, HIV, or tuberculosis before collection
- Tell the team about any prior neurological conditions — stroke, neuropathy, seizures increase ICANS risk
- Pregnancy must be excluded before treatment; Carteyva is not used in pregnancy
- Breastfeeding should be stopped; discuss timing with the treating team
- Live vaccines must be avoided around CAR-T therapy unless specifically advised by the oncologist
- Driving and operating machinery should be avoided post-infusion due to neurologic side effect risk
- Prior CD19-directed therapy should be disclosed — may affect CD19 expression and eligibility
- All current medicines, herbal supplements, and over-the-counter drugs must be declared to the team
Relmacabtagene Autoleucel in the broader treatment pathway
Carteyva is given as a standalone CAR-T infusion, but it sits within a wider treatment pathway that may involve other agents before, during, and after.
| Lymphodepleting chemotherapy (required) | Fludarabine and cyclophosphamide given before infusion to prepare the immune environment — a mandatory part of the treatment protocol |
| Bridging therapy | Steroids, chemotherapy, or targeted agents used during CAR-T manufacturing to control aggressive lymphoma progression |
| Tocilizumab and corticosteroids | Standard medicines for managing cytokine release syndrome and ICANS; given after infusion as needed |
| Antimicrobial prophylaxis | Antibacterial, antiviral, and antifungal agents given before and after infusion to prevent opportunistic infections |
| Immunoglobulin replacement | For patients with persistent B-cell aplasia and low immunoglobulin levels after CAR-T treatment |
| Next-line therapy after Carteyva | If lymphoma progresses, bispecific antibodies (glofitamab, epcoritamab), antibody-drug conjugates, chemotherapy, or transplant may be considered |
If Relmacabtagene Autoleucel stops working
Some patients may not respond to Carteyva, or may relapse after an initial response. Understanding the mechanisms guides next steps.
| Loss of CD19 expression | One of the most common mechanisms of CAR-T failure; tumour cells lose the CD19 target, making them invisible to Carteyva; reassess CD19 status by biopsy at relapse |
| Poor CAR-T cell expansion | Inadequate expansion of infused CAR-T cells can limit efficacy; may be related to prior immune suppression, poor T-cell fitness, or tumour microenvironment |
| Disease progression before CAR-T expansion | Rapidly progressing disease may outpace the CAR-T immune response before peak expansion is achieved |
| Next-line options after failure | Bispecific antibodies (CD20xCD3 or CD19xCD3), antibody-drug conjugates (loncastuximab tesirine, polatuzumab vedotin), transplant, and clinical trials are options |
| Second CAR-T therapy | Re-treatment with a different CAR-T product or CD19-directed therapy may be explored at specialist centres; discuss with the treating haematologist |
| Biopsy at relapse | Repeat biopsy is advised to confirm lymphoma subtype, re-assess CD19 status, and guide salvage therapy decisions |
Cost of Relmacabtagene Autoleucel (Carteyva)
Carteyva is one of the most complex and expensive cancer treatments available; total cost varies by centre, patient condition, and whether complications arise.
| China (domestic patients) | Chinese national insurance (NHSA) covers Carteyva under specific conditions for eligible domestic patients; out-of-pocket costs vary by hospital and province |
| China (international patients) | Full self-pay; total costs include CAR-T manufacturing, hospital stay, supportive care, tests, imaging, and medicines; costs vary by centre and duration of admission |
| Travel and logistics (international) | Costs for flights, visa, accommodation, translation, interpreter services, and caregiver support must be added for patients travelling from India, the Middle East, or other regions |
| Bridging and supportive care | Additional costs for bridging therapy, lymphodepleting chemotherapy, blood products, antimicrobials, and tocilizumab if CRS occurs |
| Outside China | Carteyva is not approved outside China; patients outside China seeking a comparable CAR-T therapy should ask their oncologist about locally approved CD19 CAR-T products |
Availability of Relmacabtagene Autoleucel globally
Carteyva is approved in China and available at qualified CAR-T centres. It is not approved in other countries as of mid-2026.
China
NMPA-approved as a Category 1 biologics product, available at qualified CAR-T centres across major cities. Domestic patients may be eligible for NHSA coverage; international patients access it on a self-pay basis.
India
Not approved. Indian patients with relapsed B-cell lymphoma seeking CAR-T options may be eligible to travel to China for Carteyva, or can ask their haematologist about locally available or trial-access CAR-T products.
Middle East / Gulf
Not approved in UAE, Saudi Arabia, or other Gulf states. Eligible patients may be considered for China CAR-T access. CancerFax can assist with medical record review and China centre coordination.
Southeast Asia / Global
Not approved in Singapore, Thailand, Malaysia, or other Southeast Asian markets. Patients from these regions may be eligible to travel to China for evaluation and treatment at a qualified centre.
Relmacabtagene autoleucel in clinical trials
Clinical research is exploring broader use of Carteyva and other CD19 CAR-T therapies across lymphoma settings.
| Earlier-line large B-cell lymphoma | Studies investigating Carteyva and CD19 CAR-T as second-line therapy instead of salvage chemotherapy plus transplant in high-risk DLBCL |
| Follicular lymphoma — expanded settings | Trials exploring CAR-T in earlier relapse settings and in higher-risk FL subtypes to improve long-term disease control |
| Post-relapse after prior CD19 CAR-T | Research examining CAR-T approaches for patients who have lost CD19 expression after prior CD19-directed therapy, including dual-target CAR constructs |
| CAR-T plus bispecific antibody sequencing | Studies evaluating the optimal sequencing of CAR-T therapy and bispecific antibodies in relapsed lymphoma to maximise durable response |
| Manufacturing improvements | Research on faster manufacturing platforms and allogeneic (off-the-shelf) CAR-T approaches to reduce time-to-treatment and improve access |
Your treatment journey with Relmacabtagene Autoleucel
Lymphoma diagnosis and subtype confirmation
CD19 testing and staging scans
Prior treatment review and CAR-T eligibility
Organ function and CAR-T centre workup
T-cell collection by leukapheresis
CAR-T manufacturing and bridging therapy
Lymphodepleting chemotherapy and infusion
Post-infusion monitoring for CRS and ICANS
Response assessment
Long-term follow-up
Questions to ask your oncologist about Relmacabtagene Autoleucel
- Is my lymphoma subtype and CD19 status appropriate for Carteyva?
- Is my disease stable enough to wait for CAR-T manufacturing?
- What are the risks of cytokine release syndrome in my situation?
- How long will I need to stay near the CAR-T centre after my infusion?
- What is the full expected cost, including all hospital and travel expenses?
- Are there other CD19 CAR-T products I should consider?
- What are my options if Carteyva does not work or the lymphoma comes back?
- What neurological side effects should my caregiver watch for after infusion?
How CancerFax supports Carteyva patients
CancerFax helps lymphoma patients and families navigate CAR-T access, understand eligibility, and coordinate treatment in China.
| Medical record review | Upload your biopsy, pathology, CD19 results, PET-CT, and treatment history — our team reviews eligibility for Carteyva and other CAR-T options |
| Specialist connection | We connect patients with haematologists and CAR-T specialists at qualified centres in China experienced in treating DLBCL, follicular lymphoma, and mantle cell lymphoma |
| China CAR-T access coordination | We manage the full access pathway for international patients — centre referral, eligibility assessment, appointment scheduling, and hospital communication |
| Second opinion | If you are unsure whether CAR-T is right for your lymphoma, CancerFax arranges an expert second opinion with a lymphoma specialist before committing to treatment |
| Travel and logistics support | For international patients travelling to China, we assist with visa guidance, interpreter services, accommodation near the centre, and caregiver planning |
| Post-CAR-T follow-up planning | We help patients coordinate monitoring scans, blood tests, immunoglobulin checks, and oncology follow-up after returning home from treatment in China |
Frequently asked questions about Relmacabtagene Autoleucel
Common questions from lymphoma patients and caregivers about Carteyva and China CAR-T therapy
Relmacabtagene autoleucel (Carteyva) is a CAR-T cell therapy made from the patient's own T cells, which are collected, engineered to recognise the CD19 protein on lymphoma cells, and infused back after a short course of chemotherapy. Unlike standard chemotherapy, which affects all rapidly dividing cells, Carteyva directs a targeted immune attack specifically against CD19-positive lymphoma cells. It is a one-time personalised cellular therapy, not a repeating drug cycle.
Adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, follicular lymphoma meeting the NMPA-approved relapsed or refractory criteria, and mantle cell lymphoma after two or more prior lines including a BTK inhibitor may be considered. Eligibility also depends on CD19-positive disease, adequate organ function, absence of uncontrolled active infection, and ability to receive care at a qualified CAR-T centre in China. Your oncologist will review all of these factors before recommending Carteyva.
The full process typically takes several weeks. After leukapheresis (T-cell collection), CAR-T manufacturing usually takes around 3 to 4 weeks, during which some patients may receive bridging therapy to control the lymphoma. Lymphodepleting chemotherapy is then given for a few days before the infusion. After the single infusion, patients are monitored closely at or near the CAR-T centre for at least 4 weeks for side effects such as cytokine release syndrome and neurologic toxicity. Total time from collection to discharge from close monitoring is typically 6 to 10 weeks.
Cytokine release syndrome, or CRS, occurs when the infused CAR-T cells become very active and release large amounts of inflammatory proteins called cytokines. It can cause fever, low blood pressure, low oxygen levels, and rapid heartbeat, and in severe cases requires ICU-level care. Most cases are manageable with tocilizumab and corticosteroids at a certified CAR-T centre. The Yescarta prescribing information includes a boxed warning for CRS because it can be life-threatening if not promptly treated.
Carteyva (relmacabtagene autoleucel) is approved by China's NMPA and is currently available only through qualified CAR-T centres in China. It is not approved by the FDA, EMA, or other major regulatory agencies outside China as of mid-2026. International patients from India, the Middle East, Southeast Asia, and other regions may be eligible to travel to China for evaluation and treatment. CancerFax can help assess your eligibility, connect you with a China CAR-T centre, and coordinate medical records, travel, and logistics.
If lymphoma progresses after Carteyva, your doctor will reassess CD19 expression on the tumour, perform repeat imaging and biopsy, and review your previous response to guide next steps. Options may include bispecific antibodies such as glofitamab or epcoritamab, antibody-drug conjugates, further chemotherapy, autologous or allogeneic stem cell transplant, or enrolment in a clinical trial. Early specialist consultation is advisable, as outcomes may differ depending on the pattern of relapse and whether the tumour has lost CD19 expression.
CAR-T therapy is among the most expensive cancer treatments available. Total costs in China include CAR-T manufacturing, hospital admission, lymphodepleting chemotherapy, supportive medicines, and monitoring, and can vary considerably by centre and patient complexity. For international patients, additional costs include travel, visa, accommodation, translation, and extended stay near the centre. Chinese national health insurance (NHSA) covers Carteyva under certain conditions for eligible domestic patients, but coverage for international patients is not available. CancerFax can discuss expected cost ranges and help plan access for your specific situation.
Prior autologous stem cell transplant does not automatically disqualify a patient, and some patients who have relapsed after transplant may still be eligible for Carteyva. Prior CD19-directed CAR-T therapy is more complex — eligibility depends on the time since prior therapy, whether CD19 expression is retained, and the pattern of relapse. Each case requires individual assessment by the CAR-T specialist team. Share all prior treatment records, including transplant details and any prior cellular therapy, when submitting for evaluation.